PET Imaging of Hepatocellular Carcinoma with 18F-fluoroethylcholine and 11C-choline

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2011 Feb 24

PMID 21344223

Citations 16

Authors

Jeffrey A Kolthammer

David J Corn

Nathan Tenley

Chunying Wu

Haibin Tian

Yanming Wang

Zhenghong Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: Choline-based radiotracers have been studied for PET imaging of hepatocellular carcinoma (HCC). Using an (18)F-labeled choline analog, instead of the (11)C-labeled native choline, would facilitate its widespread use in the clinic. In this study, PET with (18)F-fluoroethylcholine (FEC) and (11)C-choline (CHOL) were compared using an animal model of HCC. The effects of fasting on the performance of choline-based tracers were also investigated.

Methods: A woodchuck model of HCC was used to compare the two tracers, which were administered and imaged in sequence during the same imaging session. Dynamic PET images were generated spanning 50 min starting from tracer injection. Time-activity curves and tracer contrast were calculated in liver regions with tracer accumulation, and the contrast at a late time-point with the two tracers, and between fasted and nonfasted states, were compared.

Results: Foci of HCC with increased uptake ranged in size from 1.0 to 1.6 cm, with mean tumor-to-background contrast of 1.3 with FEC and 1.5 with CHOL at 50 min after injection. The tracers show similar patterns of uptake immediately following administration, and both activities plateaued at 10 min after injection. No significant differences in uptake dynamics or final contrast were observed between the fasted and nonfasted states.

Conclusion: PET imaging of HCC is possible with both CHOL and FEC. Fasting was not found to affect accumulation of either tracer. These results encourage further investigation into the clinical utility of FEC for HCC imaging.

Citing Articles

Choline metabolism and its implications in cancer.

Yao N, Li W, Xu G, Duan N, Yu G, Qu J Front Oncol. 2023; 13:1234887.

PMID: 38023163 PMC: 10646347. DOI: 10.3389/fonc.2023.1234887.

PET Imaging of Hepatocellular Carcinoma Using ZD2-(Ga-NOTA).

Sergeeva O, Zhang Y, Gao S, Ricky Chan E, Sergeev M, Iyer R J Hepatocell Carcinoma. 2023; 10:291-301.

PMID: 36860804 PMC: 9968869. DOI: 10.2147/JHC.S390939.

PET Use in Cancer Diagnosis, Treatment, and Prognosis.

Damuka N, Dodda M, Sai K Methods Mol Biol. 2022; 2413:23-35.

PMID: 35044651 PMC: 9136679. DOI: 10.1007/978-1-0716-1896-7_4.

Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer.

Suresh M, Menne S World J Gastrointest Oncol. 2021; 13(6):509-535.

PMID: 34163570 PMC: 8204361. DOI: 10.4251/wjgo.v13.i6.509.

A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness.

Lin S, Chen C, Huang B, Lai Y, Pan K, Lin S PLoS One. 2021; 16(3):e0249003.

PMID: 33755701 PMC: 7987140. DOI: 10.1371/journal.pone.0249003.

References

Salem N, MacLennan G, Kuang Y, Anderson P, Schomisch S, Tochkov I . Quantitative evaluation of 2-deoxy-2[F-18]fluoro-D-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol. 2007; 9(3):135-43. DOI: 10.1007/s11307-007-0092-5. View

Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J . The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2009; 12(1):98-107. DOI: 10.1007/s11307-009-0239-7. View

Clary G, Tsai C, Guynn R . Substrate specificity of choline kinase. Arch Biochem Biophys. 1987; 254(1):214-21. DOI: 10.1016/0003-9861(87)90097-x. View

Zeisel S . Dietary choline: biochemistry, physiology, and pharmacology. Annu Rev Nutr. 1981; 1:95-121. DOI: 10.1146/annurev.nu.01.070181.000523. View

Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A . Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med. 2008; 49(8):1245-8. DOI: 10.2967/jnumed.108.052639. View

El-Serag H, Mason A . Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340(10):745-50. DOI: 10.1056/NEJM199903113401001. View

Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y . In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995; 36(10):1811-7. View

DeGrado T, Reiman R, Price D, Wang S, Coleman R . Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med. 2002; 43(1):92-6. View

Kuang Y, Salem N, Tian H, Kolthammer J, Corn D, Wu C . Imaging lipid synthesis in hepatocellular carcinoma with [methyl-11c]choline: correlation with in vivo metabolic studies. J Nucl Med. 2010; 52(1):98-106. DOI: 10.2967/jnumed.110.080366. View

10.

Gharib A, Thomasson D, Li K . Molecular imaging of hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1):S153-8. DOI: 10.1053/j.gastro.2004.09.029. View

11.

Deves R, KRUPKA R . The binding and translocation steps in transport as related to substrate structure. A study of the choline carrier of erythrocytes. Biochim Biophys Acta. 1979; 557(2):469-85. DOI: 10.1016/0005-2736(79)90344-4. View

12.

Talbot J, Gutman F, Fartoux L, Grange J, Ganne N, Kerrou K . PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006; 33(11):1285-9. DOI: 10.1007/s00259-006-0164-9. View

13.

DeGrado T, Coleman R, Wang S, Baldwin S, Orr M, Robertson C . Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001; 61(1):110-7. View

14.

DeGrado T, Baldwin S, Wang S, Orr M, Liao R, Friedman H . Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med. 2001; 42(12):1805-14. View

15.

Hara T, Kosaka N, Kishi H . PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998; 39(6):990-5. View

16.

Talbot J, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F . Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med. 2010; 51(11):1699-706. DOI: 10.2967/jnumed.110.075507. View

17.

Fei B, Wang H, Wu C, Chiu S . Choline PET for monitoring early tumor response to photodynamic therapy. J Nucl Med. 2009; 51(1):130-8. PMC: 2999358. DOI: 10.2967/jnumed.109.067579. View

18.

Coleman , DeGrado , Wang , Baldwin , ORR , Reiman . 9:30-9:45. Preliminary Evaluation of F-18 Fluorocholine (FCH) as a PET Tumor Imaging Agent. Clin Positron Imaging. 2001; 3(4):147. DOI: 10.1016/s1095-0397(00)00059-5. View

19.

Hara T, Kosaka N, Kishi H . Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med. 2002; 43(2):187-99. View